Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Maat PharmaXPAR:MAAT +1.30%27 Days Payable is 3,287.99 as of Dec. 2025, which is 5% below its 10-year median of 3,457.63. GuruFocus rates XPAR:MAAT with a GF Score™ of 27/100 and a GF Value™ of €10.63 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 702 Biotechnology companies, Maat Pharma ranks better than 91.45% on this metric.
The historical rank and industry rank for Maat Pharma's Days Payable or its related term are showing as below:
XPAR:MAAT'
s Days Payable Range Over the Past 10 Years
Min: 2215.7 Med: 3457.63 Max: 4261.27
Current: 2677.28
During the past 8 years, Maat Pharma's highest Days Payable was 4261.27. The lowest was 2215.70. And the median was 3457.63.
XPAR:MAAT's Days Payable is ranked better than 91.45% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs XPAR:MAAT: 2677.28
Maat Pharma's Days Payable
increased
from Dec. 2024 (1,859.68) to Dec. 2025 (3,287.99).
It may suggest that Maat Pharmadelayed paying its suppliers.
Maat Pharma Days Payable Related Terms
Maat Pharma Days Payable Historical Data
* Premium members only.
The historical data trend for Maat Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:MAAT vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Maat Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maat Pharma Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Maat Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Maat Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Maat Pharma's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maat Pharma (XPAR:MAAT) has a Days Payable of 3,287.99 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Maat Pharma and its competitors. This is near median its historical median of 3,457.63. Over the past decade, Maat Pharma's Days Payable has ranged from 2,215.70 to 4,261.27. According to the industry distribution chart, Maat Pharma ranks #60 out of 702 companies in the Biotechnology industry, placing it in the top 8.5%.
Is Maat Pharma's Days Payable too high?
Maat Pharma's current Days Payable of 3,287.99 is near median its 10-year median of 3,457.63. Over the past 10 years, this metric has ranged from a low of 2,215.70 to a high of 4,261.27. The Biotechnology industry median Days Payable is 113.10. Maat Pharma's value of 3,287.99 is 2807.2% above this industry median. Based on the distribution chart, Maat Pharma ranks #60 out of 702 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Maat Pharma has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Maat Pharma's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Maat Pharma ranks #60 out of 702 companies for Days Payable. This places Maat Pharma in the top 9% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.10. Maat Pharma's value of 3,287.99 is 2807.2% above this benchmark. Historically, Maat Pharma's own Days Payable has ranged from 2,215.70 to 4,261.27 over the past decade. While the company's 10-year median is 3,457.63 vs. the industry median of 113.10, Maat Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maat Pharma's current Days Payable of 3,287.99 is 2807.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Maat Pharma and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maat Pharma's current Days Payable is 3,287.99, which is near median its own 10-year median of 3,457.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maat Pharma stock overvalued right now?
Based on GuruFocus' analysis, Maat Pharma (XPAR:MAAT) is currently considered Possible Value Trap. The stock's GF Value™ is €10.63, compared to a current price of €2.73 — trading 74.4% below its estimated fair value. The current Days Payable is 3,287.99, which is near median its 10-year median of 3,457.63 and 2807.2% above the Biotechnology industry median of 113.10. Maat Pharma's overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Maat Pharma (XPAR:MAAT), the current Days Payable is 3,287.99 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maat Pharma (XPAR:MAAT) Overvalued in 2026?
Based on GuruFocus' analysis, Maat Pharma stock appears to be undervalued.
The current stock price of €2.73 is trading 74.4% below its estimated GF Value™ of €10.63.
GuruFocus considers Maat Pharma to be Possible Value Trap.
Key valuation signals for XPAR:MAAT:
Days Payable: 3,287.99 (near median its 10-year median of 3,457.63)
GF Value™: €10.63 vs. price of €2.73 (74.4% below fair value)
Industry Position: 2807.2% above the Biotechnology median (#60 of 702)
No single metric tells the full story. See the XPAR:MAAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maat Pharma SA is a french clinical stage biotech and a pioneer in the development of microbiome based ecosystem therapies dedicated to improving survival outcomes for patients with cancer.
27GF Score
Get the complete analysis for XPAR:MAAT
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:MAAT has been successfully added to your 
